{"id":"omalizumab-injection","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Injection site reaction"},{"rate":"5-8","effect":"Headache"},{"rate":"5-7","effect":"Upper respiratory tract infection"},{"rate":"3-5","effect":"Arthralgia"},{"rate":"0.1-0.2","effect":"Anaphylaxis"}]},"_chembl":{"chemblId":"CHEMBL1201589","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By sequestering free IgE, omalizumab reduces the activation of mast cells and basophils that would otherwise occur upon allergen exposure. This prevents the release of inflammatory mediators (histamine, tryptase, leukotrienes) that drive allergic and asthmatic responses. The reduction in IgE-mediated inflammation leads to decreased symptoms and improved disease control in allergic conditions.","oneSentence":"Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing IgE from interacting with high-affinity IgE receptors on mast cells and basophils.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:11.715Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe allergic asthma"},{"name":"Chronic idiopathic urticaria"},{"name":"Allergic rhinitis"},{"name":"Food allergy"}]},"trialDetails":[{"nctId":"NCT04648930","phase":"","title":"Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-27","conditions":"Allergic Rhinitis","enrollment":50},{"nctId":"NCT06929052","phase":"PHASE1","title":"A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects.","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2025-01-29","conditions":"Healthy Adult Subjects","enrollment":150},{"nctId":"NCT07356713","phase":"PHASE1","title":"A Study to Find a Suitable Dose of Exl-111 for Further Research","status":"RECRUITING","sponsor":"Excellergy Inc.","startDate":"2026-01-08","conditions":"Allergic Disease","enrollment":70},{"nctId":"NCT07059091","phase":"PHASE2","title":"Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-02-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Allergies","enrollment":334},{"nctId":"NCT06943534","phase":"PHASE2","title":"Omalizumab Weight-Based Dosing Efficacy Trial","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-07-03","conditions":"Allergies, Food Allergy","enrollment":30},{"nctId":"NCT07342803","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients","status":"RECRUITING","sponsor":"Longbio Pharma","startDate":"2025-01-25","conditions":"Allergic Asthma","enrollment":200},{"nctId":"NCT03369704","phase":"PHASE3","title":"Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-15","conditions":"Seasonal Allergic Rhinitis","enrollment":337},{"nctId":"NCT02570984","phase":"PHASE2","title":"Preventing Asthma in High Risk Kids","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2018-11-27","conditions":"Asthma","enrollment":200},{"nctId":"NCT07246252","phase":"PHASE1","title":"Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2024-03-28","conditions":"Healthy Volunteers (HV)","enrollment":114},{"nctId":"NCT04361812","phase":"PHASE1","title":"Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection","status":"TERMINATED","sponsor":"BioRay Pharmaceutical Co., Ltd.","startDate":"2020-10-15","conditions":"Similarity of Pharmacokinetics and Safety","enrollment":1},{"nctId":"NCT05626257","phase":"","title":"Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-01-12","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":135},{"nctId":"NCT06365879","phase":"PHASE3","title":"To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria","status":"RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2024-06-18","conditions":"Chronic Spontaneous Urticaria","enrollment":392},{"nctId":"NCT04998604","phase":"PHASE4","title":"EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-09-27","conditions":"Chronic Rhinosinusitis With Nasal Polyps, Asthma","enrollment":360},{"nctId":"NCT04976192","phase":"PHASE3","title":"Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2021-08-30","conditions":"Chronic Urticaria","enrollment":608},{"nctId":"NCT03881696","phase":"PHASE3","title":"Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-07-22","conditions":"Peanut Allergy, Multi-food Allergy","enrollment":471},{"nctId":"NCT04180488","phase":"PHASE3","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-11","conditions":"Chronic Spontaneous Urticaria","enrollment":397},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06437171","phase":"PHASE4","title":"FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA","status":"ACTIVE_NOT_RECRUITING","sponsor":"AAADRS Clinical Research Center","startDate":"2024-06-03","conditions":"Food Allergy","enrollment":20},{"nctId":"NCT07073404","phase":"","title":"Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or Profilin","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2026-01","conditions":"Food Allergies","enrollment":37},{"nctId":"NCT05332067","phase":"PHASE2","title":"Omalizumab Before Onset of Exacerbations","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2022-05-01","conditions":"Asthma in Children, Atopy, Viral Upper Respiratory Infection","enrollment":300},{"nctId":"NCT05053334","phase":"PHASE1","title":"Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair","status":"COMPLETED","sponsor":"Syneos Health","startDate":"2022-02-16","conditions":"Healthy Volunteers","enrollment":165},{"nctId":"NCT06934200","phase":"PHASE2","title":"Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-05-19","conditions":"Food Hypersensitivity","enrollment":32},{"nctId":"NCT06618963","phase":"PHASE4","title":"Effect of Omalizumab in the Skin of Food Allergy Patients","status":"RECRUITING","sponsor":"National Jewish Health","startDate":"2024-10-01","conditions":"Food Allergy, Food Allergy in Children","enrollment":40},{"nctId":"NCT04833855","phase":"PHASE2","title":"Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-04-15","conditions":"Chronic Spontaneous Urticaria","enrollment":183},{"nctId":"NCT03727971","phase":"PHASE2","title":"Treatment With the Anti-IgE Monoclonal Antibody Omalizumab in Women With Asthma Undergoing Fertility Treatment. - A Proof of Concept Study.","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-01-01","conditions":"Asthma, Infertility, Female","enrollment":66},{"nctId":"NCT05564611","phase":"PHASE1","title":"PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2022-11-04","conditions":"Healthy","enrollment":204},{"nctId":"NCT05774639","phase":"PHASE3","title":"Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2023-08-15","conditions":"Chronic Idiopathic Urticaria","enrollment":600},{"nctId":"NCT05564221","phase":"PHASE1","title":"A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2022-11-01","conditions":"Atopic Healthy Subjects, Adult Subjects With Allergic Diseases","enrollment":46},{"nctId":"NCT06771934","phase":"","title":"Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2024-06-01","conditions":"Allergic Asthma","enrollment":60},{"nctId":"NCT03580356","phase":"PHASE3","title":"A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-20","conditions":"Chronic Spontaneous Urticaria","enrollment":1078},{"nctId":"NCT05061524","phase":"PHASE1","title":"A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2021-09-26","conditions":"Atopic Healthy Subjects, Adult Subjects with Mild Allergic Diseases","enrollment":68},{"nctId":"NCT06509334","phase":"PHASE2","title":"Trial of JYB1904 in Chronic Spontaneous Urticaria.","status":"RECRUITING","sponsor":"Jemincare","startDate":"2024-08-04","conditions":"Chronic Spontaneous Urticaria","enrollment":135},{"nctId":"NCT05960708","phase":"PHASE1","title":"A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2023-08-23","conditions":"Allergic Disease, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria","enrollment":30},{"nctId":"NCT06535087","phase":"","title":"The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","status":"RECRUITING","sponsor":"Wenjing Zhou","startDate":"2024-07-20","conditions":"Pediatric Asthma, Rhinitis, Allergic, Quality of Life","enrollment":600},{"nctId":"NCT03964051","phase":"PHASE4","title":"Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).","status":"TERMINATED","sponsor":"Carsten Bindslev-Jensen","startDate":"2019-07-01","conditions":"Food Allergy","enrollment":7},{"nctId":"NCT04037176","phase":"PHASE4","title":"Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)","status":"COMPLETED","sponsor":"Carsten Bindslev-Jensen","startDate":"2019-11-01","conditions":"Food Allergy","enrollment":20},{"nctId":"NCT03580369","phase":"PHASE3","title":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-17","conditions":"Chronic Spontaneous Urticaria","enrollment":1072},{"nctId":"NCT05413161","phase":"PHASE1","title":"To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2022-07-07","conditions":"Healthy","enrollment":306},{"nctId":"NCT05449535","phase":"PHASE1","title":"Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Jemincare","startDate":"2022-05-07","conditions":"Healthy","enrollment":56},{"nctId":"NCT05897008","phase":"PHASE1","title":"The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity","status":"COMPLETED","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2022-02-07","conditions":"Healthy Volunteers","enrollment":114},{"nctId":"NCT04018313","phase":"PHASE1","title":"To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-05-28","conditions":"Healthy","enrollment":176},{"nctId":"NCT05813470","phase":"PHASE3","title":"Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2021-01-18","conditions":"Allergic Asthma, Uncontrolled Moderate to Severe","enrollment":256},{"nctId":"NCT01781637","phase":"PHASE1, PHASE2","title":"Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-01","conditions":"Peanut Allergy, Food Allergy","enrollment":36},{"nctId":"NCT02966314","phase":"PHASE4","title":"Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-03-30","conditions":"Idiopathic Angioedema","enrollment":12},{"nctId":"NCT05405478","phase":"PHASE4","title":"Omalizumab Efficacy in Patients With Refractory Nasal Polyps","status":"UNKNOWN","sponsor":"Shiraz University of Medical Sciences","startDate":"2022-06-01","conditions":"Nasal Polyps","enrollment":2},{"nctId":"NCT01716312","phase":"PHASE1","title":"Omalizumab for Lupus","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2014-01-08","conditions":"Systemic Lupus Erthematosus, Sjogren's Syndrome","enrollment":17},{"nctId":"NCT03478930","phase":"PHASE3","title":"An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-05-09","conditions":"Nasal Polyps, Chronic Rhinosinusitis","enrollment":249},{"nctId":"NCT04195958","phase":"PHASE4","title":"A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2020-11-30","conditions":"Moderate-to-severe Allergic Asthma","enrollment":3},{"nctId":"NCT05129033","phase":"NA","title":"A Prospective Study on Optimizing Treatment for ABPA","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-11-15","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":100},{"nctId":"NCT04535817","phase":"PHASE1","title":"Xolair Interventional Study in ASD Patients With Comorbid Atopy","status":"WITHDRAWN","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2021-01-01","conditions":"Autism Spectrum Disorder, Atopy","enrollment":""},{"nctId":"NCT00367016","phase":"PHASE4","title":"Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2004-02","conditions":"Asthma, Allergic Rhinitis, Atopic Dermatitis","enrollment":6},{"nctId":"NCT04944602","phase":"PHASE3","title":"Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2021-07","conditions":"Chronic Spontaneous Urticaria","enrollment":340},{"nctId":"NCT03111628","phase":"PHASE4","title":"Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-10-06","conditions":"Urticaria Chronic","enrollment":18},{"nctId":"NCT04489121","phase":"NA","title":"The Efficacy of Preseasonal Omalizumab Treatment","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2020-07-28","conditions":"Seasonal Allergic Rhinitis","enrollment":31},{"nctId":"NCT02477332","phase":"PHASE2","title":"Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-15","conditions":"Chronic Spontaneous Urticaria","enrollment":382},{"nctId":"NCT03328897","phase":"PHASE3","title":"Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-04-26","conditions":"Chronic Spontaneous Urticaria","enrollment":418},{"nctId":"NCT04585997","phase":"PHASE4","title":"Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - \"Choosebetweenamab\".","status":"UNKNOWN","sponsor":"University of Newcastle, Australia","startDate":"2018-11-03","conditions":"Asthma, Eosinophilic Asthma","enrollment":200},{"nctId":"NCT01723072","phase":"PHASE3","title":"Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-23","conditions":"Chronic Spontaneous Urticaria, Angioedema","enrollment":91},{"nctId":"NCT01157117","phase":"PHASE2","title":"OIT and Xolair® (Omalizumab) in Cow's Milk Allergy","status":"COMPLETED","sponsor":"Hugh A Sampson, MD","startDate":"2010-08","conditions":"Milk Allergy","enrollment":77},{"nctId":"NCT03280550","phase":"PHASE3","title":"A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-11-15","conditions":"Nasal Polyps, Chronic Rhinosinusitis","enrollment":138},{"nctId":"NCT03280537","phase":"PHASE3","title":"A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-11-21","conditions":"Nasal Polyps, Chronic Rhinosinusitis","enrollment":127},{"nctId":"NCT02550106","phase":"PHASE4","title":"Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04-22","conditions":"CHRONIC SPONTANEOUS URTICARIA","enrollment":136},{"nctId":"NCT04210323","phase":"NA","title":"Shotblocker® Use in Subcutaneous Injection","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2018-06-05","conditions":"Chronic Spontaneous Urticaria","enrollment":90},{"nctId":"NCT02658877","phase":"PHASE4","title":"Sputum-derived Cellular Targets After Xolair (Omalizumab)","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2016-01","conditions":"Asthma","enrollment":3},{"nctId":"NCT01912872","phase":"PHASE4","title":"Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-11","conditions":"Severe IgE-mediated Asthma","enrollment":112},{"nctId":"NCT02012387","phase":"PHASE2","title":"Efficacy Study of Omalizumab in Cholinergic Urticaria","status":"COMPLETED","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2014-01","conditions":"Cholinergic Urticaria","enrollment":24},{"nctId":"NCT02814630","phase":"NA","title":"Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Asthma Inc Clinical Research Center","startDate":"2016-09","conditions":"Chronic Idiopathic Urticaria","enrollment":20},{"nctId":"NCT02161562","phase":"PHASE3","title":"OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-01","conditions":"Chronic Spontaneous Urticaria","enrollment":314},{"nctId":"NCT00264849","phase":"PHASE4","title":"Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Asthma","enrollment":406},{"nctId":"NCT00932282","phase":"PHASE1, PHASE2","title":"Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-07","conditions":"Peanut Hypersensitivity","enrollment":13},{"nctId":"NCT02643862","phase":"PHASE1, PHASE2","title":"Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients","status":"COMPLETED","sponsor":"Stanford University","startDate":"2015-03-18","conditions":"Food Allergy","enrollment":48},{"nctId":"NCT02626611","phase":"PHASE2","title":"Multi Immunotherapy to Test Tolerance and Xolair","status":"COMPLETED","sponsor":"Kari Christine Nadeau","startDate":"2015-12","conditions":"Food Allergy","enrollment":70},{"nctId":"NCT01713725","phase":"PHASE2","title":"Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria","status":"COMPLETED","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2012-03","conditions":"Chronic Urticaria","enrollment":20},{"nctId":"NCT00162773","phase":"PHASE2","title":"Effect of Anti-IgE in Non-Allergic Asthma","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2005-04","conditions":"Asthma","enrollment":29},{"nctId":"NCT00866788","phase":"PHASE2","title":"A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-03","conditions":"Chronic Idiopathic Urticaria","enrollment":90},{"nctId":"NCT01066104","phase":"PHASE2","title":"Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-12","conditions":"Chronic Rhinosinusitis, Nasal Polyps","enrollment":27},{"nctId":"NCT00777764","phase":"PHASE4","title":"The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-08","conditions":"Healthy, Asthma","enrollment":60},{"nctId":"NCT00096954","phase":"PHASE4","title":"A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-02","conditions":"Asthma","enrollment":333},{"nctId":"NCT00495612","phase":"PHASE4","title":"A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-09","conditions":"Asthma","enrollment":69},{"nctId":"NCT01430403","phase":"PHASE4","title":"Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Asthma","enrollment":478},{"nctId":"NCT00604786","phase":"NA","title":"The Effect of Omalizumab on Responses to Cat Allergen Challenge","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-07","conditions":"Allergic Rhinitis","enrollment":18},{"nctId":"NCT00377572","phase":"PHASE4","title":"Inner-City Anti-IgE Therapy for Asthma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Asthma","enrollment":419},{"nctId":"NCT01328886","phase":"PHASE3","title":"Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":"Allergic Asthma","enrollment":38},{"nctId":"NCT00078195","phase":"PHASE2","title":"Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-04","conditions":"Hay Fever, Hypersensitivity, Allergy","enrollment":168},{"nctId":"NCT00267202","phase":"PHASE4","title":"Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Allergic Asthma","enrollment":275},{"nctId":"NCT01703312","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Allergic Asthma","enrollment":37},{"nctId":"NCT00829179","phase":"PHASE3","title":"Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma","status":"COMPLETED","sponsor":"Duke University","startDate":"2002-10","conditions":"Allergic Asthma","enrollment":20},{"nctId":"NCT01333293","phase":"PHASE2, PHASE3","title":"The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2011-09","conditions":"Mastocytosis","enrollment":17},{"nctId":"NCT01976208","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma","status":"COMPLETED","sponsor":"Shanghai Zhangjiang Biotechnology Limited Company","startDate":"2010-12","conditions":"Allergic Asthma","enrollment":630},{"nctId":"NCT01202903","phase":"PHASE3","title":"Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Persistent Allergic Asthma","enrollment":616},{"nctId":"NCT01544348","phase":"PHASE1","title":"A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-01","conditions":"Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis","enrollment":295},{"nctId":"NCT01125748","phase":"PHASE4","title":"A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-05","conditions":"Allergic Asthma","enrollment":176},{"nctId":"NCT01003301","phase":"PHASE2","title":"The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-10","conditions":"Cat Allergy","enrollment":19},{"nctId":"NCT00657891","phase":"PHASE4","title":"The Effect of Xolair (Omalizumab) on Allergy Blood Cells","status":"COMPLETED","sponsor":"Creighton University","startDate":"2007-03","conditions":"Asthma","enrollment":49},{"nctId":"NCT00377390","phase":"","title":"ICATA Asthma Mechanistic Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Asthma","enrollment":224},{"nctId":"NCT00670930","phase":"PHASE4","title":"Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Allergic Asthma","enrollment":36},{"nctId":"NCT01007149","phase":"PHASE3","title":"Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Asthma","enrollment":79},{"nctId":"NCT00673218","phase":"PHASE4","title":"The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils","status":"UNKNOWN","sponsor":"Creighton University","startDate":"2007-06","conditions":"Allergy","enrollment":25},{"nctId":"NCT00079937","phase":"PHASE3","title":"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-04","conditions":"Asthma","enrollment":628},{"nctId":"NCT01040598","phase":"PHASE1","title":"Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model","status":"COMPLETED","sponsor":"O & O Alpan LLC","startDate":"2009-06","conditions":"Eosinophilic Esophagitis","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xolair","ADL-018","Xolair 300 mg","Omlyclo","Placebo Xolair®"],"phase":"marketed","status":"active","brandName":"Omalizumab Injection","genericName":"Omalizumab Injection","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing IgE from interacting with high-affinity IgE receptors on mast cells and basophils. Used for Moderate to severe allergic asthma, Chronic idiopathic urticaria, Nasal polyposis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}